Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele

Prior, Noemí Pérez; Milla, Amparo Rocher; Cid, Juan Flores; Chust, Benjamín Sarriá

doi:10.1016/s2173-5085(09)70081-4

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have shown that the risk of abacavir hypersensitivity reactions (ABC-HSR) is strongly associated with the presence of the human leukocyte antigen HLA-B*57:01 [11][12][13]. Indeed, the effectiveness of prospective HLA-B*57:01 screening in preventing ABC-related hypersensitivity reactions was demonstrated [14].…”

Section: Introductionmentioning

confidence: 99%

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

ADECHINA

ASSOGBA

Tchiakpé

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Antiretroviral drugs in people living with HIV-1 (PLHIV-1) often trigger side effects which may lead to discontinuation or failure of treatment. Human Leukocyte Antigen B*57:01 (HLA-B*57:01) allele is known to predict hypersensitivity reactions to Abacavir. Very few data are available on the prevalence of HLA-B*57:01 allele in PLHIV-1 in African countries. This study aimed to screen for HLA-B*57:01 allele in PLHIV-1 in Benin. Methods: This pilot study was carried out on one hundred ten PLHIV-1 enrolled in two health facilities in Benin. Socio-demographic and clinical data were collected. Biological data were determined and HLA-B*57:01 allele was genotyped, using Single Specific Primer-Polymerase Chain Reaction in blood samples. Results: Seventy percent of participants were female. PLHIV-1 were under TDF+3TC+DTG (47.2%) or TDF+3TC+EFV (57.3%). Their median age was 41 [36-48.75] years and the average CD4+ T cell count was 249 [130-381.25] cells/µl. The average viral load in treatment failure PLHIV-1 was 4.7 [3.9-5.2] Log10. At the inclusion date, twenty-nine (26.4%) PLHIV-1 under TDF+3TC+EFV have developed hypersensitivity reactions. None of 110 patients had shown HLA-B*5701 allele. Conclusion: Our study revealed that HLA-B*57:01 allele was very rare in PLHIV-1 in Benin, suggesting that its screening before starting the Abacavir regimen did not seem necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

ADECHINA

ASSOGBA

Tchiakpé

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Clinical Abacavir Hypersensitivity Reaction among Children in India

et al. 2016

View full text Add to dashboard Cite

Abacavir is currently recommended as a part of first line regimen by National AIDS Control Organization. The objective of this study was to observe the incidence of clinically diagnosed abacavir Hypersensitivity reaction (HSR) among children on abacavir based therapy in the National program. In this observational study, all children started on abacavir were included and HSR reaction was diagnosed clinically as per National guidelines. HLA- B*5701 testing was done in children diagnosed with clinical abacavir HSR. Among 101 children started on abacavir during the study period, 8 [7.9 % (95 % CI 3.5-15.0 %)] children developed clinically diagnosed abacavir HSR. All children with concomitant illness (4/8) were HLA-B*5701 negative. Only 2 (25 %, 2/8) carried HLA-B*5701 allele. Fever with abdominal symptoms as compared to respiratory symptoms were more common in HLA-B*5701 positive cases. Overdiagnosis of clinically diagnosed abacavir HSR is common and could be decreased by treating concomitant illness before starting abacavir.

show abstract

Validation of a Rapid Test for HLA-B58:01/57:01* Allele Screening to Detect Individuals at Risk for Drug-Induced Hypersensitivity

Nguyen

Vidal

et al. 2016

Pharmacogenomics

View full text Add to dashboard Cite

show abstract

Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele

Cited by 3 publications

References 22 publications

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

Clinical Abacavir Hypersensitivity Reaction among Children in India

Validation of a Rapid Test for HLA-B58:01/57:01* Allele Screening to Detect Individuals at Risk for Drug-Induced Hypersensitivity

Contact Info

Product

Resources

About

Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele

Cited by 3 publications

References 22 publications

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study

Clinical Abacavir Hypersensitivity Reaction among Children in India

Validation of a Rapid Test for HLA-B*58:01/57:01 Allele Screening to Detect Individuals at Risk for Drug-Induced Hypersensitivity

Contact Info

Product

Resources

About

Validation of a Rapid Test for HLA-B58:01/57:01* Allele Screening to Detect Individuals at Risk for Drug-Induced Hypersensitivity